Abeona Therapeutics updates investor presentation

Q: What did ABEO disclose in its September 15, 2026 Form 8-K?

Abeona Therapeutics Inc. furnished an updated investor presentation as Exhibit 99.1, which it expects to use at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, under a Regulation FD disclosure item.

Q: What is Exhibit 99.1 in Abeona Therapeutics' (ABEO) 8-K?

Exhibit 99.1 is an Abeona Therapeutics Inc. presentation dated September 15, 2026, titled “H.C. Wainwright 28th Annual Global Investment Conference,” which the company expects to use at that conference.

Q: Which 8-K item did Abeona (ABEO) use for this disclosure?

Abeona used Item 7.01, Regulation FD Disclosure, to furnish its updated investor presentation associated with the H.C. Wainwright 28th Annual Global Investment Conference.

Abeona Therapeutics Inc. (ABEO) furnished an updated investor presentation as a Regulation FD disclosure in connection with its participation on September 15, 2026 at the H.C.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Abeona Therapeutics Inc. (ABEO) furnished an updated investor presentation as a Regulation FD disclosure in connection with its participation on September 15, 2026 at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is provided as Exhibit 99.1 to this report.

The company states that the materials in Item 7.01, including Exhibit 99.1, are being furnished rather than filed under the Exchange Act and will only be incorporated into other securities law filings if specifically referenced.

Insights

Analyzing...

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD, Emerging growth company, Inline XBRL

3 terms

Regulation FD regulatory

"Item 7.01. Regulation FD Disclosure"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ABEO disclose in its September 15, 2026 Form 8-K?

Abeona Therapeutics Inc. furnished an updated investor presentation as Exhibit 99.1, which it expects to use at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, under a Regulation FD disclosure item.

How is the new Abeona (ABEO) investor presentation treated under securities laws?

Abeona states the investor presentation in Item 7.01, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, and it is not subject to Section 18 liabilities or incorporated into Securities Act filings unless specifically referenced.

What is Exhibit 99.1 in Abeona Therapeutics' (ABEO) 8-K?

Exhibit 99.1 is an Abeona Therapeutics Inc. presentation dated September 15, 2026, titled “H.C. Wainwright 28th Annual Global Investment Conference,” which the company expects to use at that conference.

Which 8-K item did Abeona (ABEO) use for this disclosure?

Abeona used Item 7.01, Regulation FD Disclosure, to furnish its updated investor presentation associated with the H.C. Wainwright 28th Annual Global Investment Conference.

Who signed Abeona Therapeutics' (ABEO) September 15, 2026 Form 8-K?

The Form 8-K was signed on behalf of Abeona Therapeutics Inc. by Joseph Vazzano, who is identified as the company’s Chief Financial Officer, dated September 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/15/2026 - 12:00 PM Accepted by SEC EDGAR 09/15/2026 - 12:00 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 15, 2026

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-15771

83-0221517

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

6555 Carnegie Ave, 4th Floor

Cleveland, OH 44103

(Address of principal executive offices) (Zip Code)

(646) 813-4701

(Registrant’s telephone number, including area code)

N /A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ABEO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Abeona Therapeutics Inc. is furnishing in this Current Report on Form 8-K an updated investor presentation (the “Investor Presentation”) that it expects to use, either in whole or in part, on September 15, 2026 at the H.C. Wainwright 28th Annual Global Investment Conference. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Abeona Therapeutics Inc. Presentation, dated September 15, 2026, entitled “H.C. Wainwright 28th Annual Global Investment Conference”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.